We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Successful Cardiac Repair Depends on Maturity of Transplanted Stem Cells

By LabMedica International staff writers
Posted on 18 Jan 2016
A team of Japanese cells biologists has shown that the likelihood of stem cell therapy successfully repairing damaged heart muscle depends to large extent on the maturity of the stem cells at the time they are transplanted into the damaged organ.

Although transplantation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) has been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. More...


To better optimize CMs for transplantation, investigators at Kyoto University (Japan) used in vivo bioluminescence imaging to compare the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day four mesodermal cells, and purified iPSC-CMs 8 days, 20 days, and 30 days after initial differentiation.

They reported in the January 8, 2016, online edition of the journal Scientific Reports that the engraftment efficiency of day 20 CMs was significantly higher compared to other cell populations. Transplantation of day 20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment, and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal at three months post injection indicated engrafted CMs proliferated in the host heart. These results suggested that day 20 CMs had very high engraftment, proliferation, and therapeutic potential in host mouse hearts.

"Cells of different maturation will be mixed and transplanted together, but heart cells at different stages could behave very differently," said first author Dr. Shunsuke Fukakoshi. "We need to test animals bigger than mice."

Related Links:

Kyoto University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.